For Insulin Resistance Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.



Get Sample Report @ https://www.wiseguyreports.com/sample-request/619271-marburg-hemorrhagic-fever-pipeline-review-h2-2016



Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.



The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



Scope

- The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever

- The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects

- The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever



Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Marburg Hemorrhagic Fever Overview 8

Therapeutics Development 9

Pipeline Products for Marburg Hemorrhagic Fever - Overview 9

Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis 10

Marburg Hemorrhagic Fever - Therapeutics under Development by Companies 11

Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 12

Marburg Hemorrhagic Fever - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Marburg Hemorrhagic Fever - Products under Development by Companies 16

Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes 17

Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development 18

Arno Therapeutics, Inc. 18

BioCryst Pharmaceuticals, Inc. 19

GeoVax Labs, Inc. 20

GlaxoSmithKline Plc 21

Integrated BioTherapeutics, Inc. 22

Johnson & Johnson 23

NanoViricides, Inc. 24

Profectus BioSciences, Inc. 25

Sarepta Therapeutics, Inc. 26

Marburg Hemorrhagic Fever - Therapeutics Assessment 27



Access Report @ https://www.wiseguyreports.com/reports/619271-marburg-hemorrhagic-fever-pipeline-review-h2-2016


Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.